Post-Traumatic Stress Disorder (PTSD) Clinical Trials

Find Post-Traumatic Stress Disorder (PTSD) Clinical Trials Near You

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study will examine the safety and efficacy of BXCL501 to reduce ASR symptoms and behavioral changes among patients presenting to the Emergency Department (ED) after Motor Vehicle Collision (MVC). Specifically, the investigators will perform the BXCL501 (BASIS) Trial, a double-blind placebo-controlled Randomized Controlled Trial (RCT) to determine if BXCL501 (dexmedetomidine hydrochloride sublingual film) initiated in the ED in the hours after MVC to high risk individuals, treats/reduces ASR/ASD symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 100 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• ≥ 18 years and ≤ 65 years of age

• Admitted to ED within 72 hours of MVC

• Anticipated to be discharged home from the ED

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Consent to receive unencrypted communications

• Has a smartphone with continuous service for ≥ 1 year

• Has a personal email address they regularly access

• Able to speak and read English

• Females of childbearing potential (not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for \> 12 months)) must be willing to use a medically acceptable and effective birth control method for 3 months before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms

Locations
United States
Florida
University of Florida College of Medicine - Jacksonville
RECRUITING
Jacksonville
Missouri
Washington University in St. Louis
NOT_YET_RECRUITING
St Louis
Virginia
UVA University Hospital
RECRUITING
Charlottesville
Contact Information
Primary
Romina Soudavari, MPH
romina_soudavari@med.unc.edu
9843195030
Time Frame
Start Date: 2026-02-23
Estimated Completion Date: 2026-09-29
Participants
Target number of participants: 100
Treatments
Experimental: BXCL501 (dexmedetomidine HCl)
Participants will be instructed to take an initial dose of BXCL501 (equivalent to 1 film, 120mcg) in the ED as part of enrollment procedures. If the time between the first dose and the planned bedtime of the participant is greater than 6 hours, participants will be instructed to take the second dose at bedtime on the day of enrollment. If the time between the first dose and the planned bedtime of the participant is less than 6 hours participants will be instructed to take the second dose before bedtime on the day following enrollment. Following the initial dosing on the day of enrollment, all participants will be instructed to take a dose of study medication before bedtime until they have completed 14 days of treatment.
Placebo_comparator: Placebo
Participants will be instructed to take an initial dose of placebo (equivalent to 1 film, 120mcg) in the ED as part of enrollment procedures. If the time between the first dose and the planned bedtime of the participant is greater than 6 hours, participants will be instructed to take the second dose at bedtime on the day of enrollment. If the time between the first dose and the planned bedtime of the participant is less than 6 hours participants will be instructed to take the second dose before bedtime on the day following enrollment. Following the initial dosing on the day of enrollment, all participants will be instructed to take a dose of study medication before bedtime until they have completed 14 days of treatment.
Related Therapeutic Areas
Sponsors
Collaborators: Washington University School of Medicine, United States Department of Defense, University of Florida, Rhode Island Hospital, Walter Reed Army Institute of Research (WRAIR), Vanderbilt University School of Medicine, Mclean Hospital
Leads: University of North Carolina, Chapel Hill

This content was sourced from clinicaltrials.gov